SFX-01 in the Treatment and Evaluation of Metastatic Breast Cancer
Status:
Completed
Trial end date:
2019-03-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2 study to demonstrate the safety and efficacy of SFX-01 when used in
combination with aromatase inhibitors (AIs), tamoxifen and fulvestrant.
Patients will be enrolled into one of three study arms (SFX-01 in combination with AI,
tamoxifen or fulvestrant) based on their current therapy.